Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
Tempest Therapeutics
Incyte Corporation
PharmaMar
Exelixis
Compugen Ltd
Acepodia Biotech, Inc.
Vincerx Pharma, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xencor, Inc.
Prelude Therapeutics
NextCure, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Incyte Corporation
MacroGenics
Incyte Corporation
Seagen Inc.
Gilead Sciences
Eisai Inc.
Seagen Inc.
Ciusss de L'Est de l'Île de Montréal
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Amgen
Santa Maria Biotherapeutics
University of Southern California
BIND Therapeutics
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sanofi
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Netherlands Open University
University of New Mexico
Pharmacyclics LLC.
SCRI Development Innovations, LLC